| 1 |
35352593 | CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. | 2022 Mar 30 |
4 |
| 2 |
32324953 | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. | 2021 Jan |
2 |
| 3 |
32708961 | Formulation of Sustained Release Hydrophilic Matrix Tablets of Tolcapone with the Application of Sedem Diagram: Influence of Tolcapone's Particle Size on Sustained Release. | 2020 Jul 17 |
1 |
| 4 |
32791384 | Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin. | 2020 Oct |
6 |
| 5 |
31119947 | Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. | 2019 Jun |
9 |
| 6 |
28298647 | Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. | 2017 Mar 15 |
2 |
| 7 |
26902880 | Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. | 2016 Feb 23 |
7 |